"Dr. Kulleni Gebreyes, principal at Deloitte and vice chair and U.S. life sciences & health care industry leader, said that women's health should be seen as human health. "It's not a niche market, it's not arts and crafts, it's greater than 50% of the population of the world. Anyone who tells you differently has an economic blind spot." She noted that data is the new infrastructure and trust is the new currency."
""There's a lot of systemic bias that we need to understand and focus on, so that women's health pharmaceutical innovation and medical health innovation can become infused with a women's perspective," Adams said. She pointed to stark disparities: "Women have twice the amount of anxiety and depression that men do, 60% of Alzheimer's patients are women, one in five women have a depression or anxiety event every year that requires treatment, and yet less than 30% of clinical trials in those spaces are on women.""
Women's health must be treated as human health rather than a niche, because women represent more than half the global population and exclusion creates an economic blind spot. Data is the new infrastructure and trust is the new currency; women want transparency about how data will be used to drive better outcomes. Six out of ten wearable users are women, yet only 20% of women say digital platforms are customized for them. Pharmaceutical development often overlooks women; systemic bias and lack of women's leadership hinder innovation. Women experience disproportionate mental health and Alzheimer's burdens and remain underrepresented in related clinical trials. Susan G. Komen is a leading funder of breast cancer drug research.
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]